Steven Gillis's Net Worth

$642 Million

Estimate Recalculated Feb 20, 2024 05:43PM EST

Who is Steven Gillis?

Steven Gillis has an estimated net worth of $642 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., VBI VACCINES INC., PHASERX, INC., Neumora Therapeutics, Inc., Trubion Pharmaceuticals, Inc, VBI Vaccines Inc/BC, DA32 Life Science Tech Acquisition Corp., Erasca, Inc., Pulmatrix, Inc., Verve Therapeutics, Inc., bluebird bio, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Homology Medicines, Inc., Prime Medicine, Inc., and CORIXA CORP.

SEC CIK

Steven Gillis's CIK is 0001229592

Past Insider Trading and Trends

2023 was Steven Gillis's most active year for acquiring shares with 29 total transactions. Steven Gillis's most active month to acquire stocks was the month of May. 2005 was Steven Gillis's most active year for disposing of shares, totalling 22 transactions. Steven Gillis's most active month to dispose stocks was the month of June. 2023 saw Steven Gillis paying a total of $32,435,022.58 for 20,200,108 shares, this is the most they've acquired in one year. In 2014 Steven Gillis cashed out on 752,477 shares for a total of $9,305,060.48, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Sana Biotechnology, Inc. (SANA) Snapshot price: $6.145

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+5.39%
1.82M
$5.50
$9,999,995.50
35.56M
Feb 8
Form 4
+14,957.26%
43.75M
44.04M
Feb 8
Form 3
0
0
No matching records found

PHASERX, INC. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
May 25
Form 4
0
0
Jun 1
Form 4
+12.62%
319.94K
$2.51
$4,993,199.41
2.85M
May 23
Form 3/A
0
0
Form 3
0
0
No matching records found

Neumora Therapeutics, Inc. (NMRA) Snapshot price: $16.9617

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+102.76%
1.88M
3.71M
Dec 8
Form 4
+0.85%
35.01K
$11.77
$412,139.61
4.13M
Nov 13 - Nov 14
Form 4
+3.55%
140.6K
$10.98
$1,543,563.42
4.1M
Nov 8 - Nov 10
Form 4
+2.48%
95.69K
$11.49
$1,099,944.70
3.96M
Nov 3 - Nov 7
Form 4
+2.02%
76.51K
$13.68
$1,046,848.16
3.86M
Sep 28 - Sep 29
Form 4
+1.57%
58.5K
$11.97
$700,464.24
3.78M
Sep 26 - Sep 27
Form 4
+2.78%
100.74K
$11.19
$1,127,063.95
3.72M
Sep 22 - Sep 25
Form 4
+178.19%
18.92M
$17.00
29.55M
Sep 19
Form 3
0
0
No matching records found

Erasca, Inc. (ERAS) Snapshot price: $1.705

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
11.06M
11.06M
Jul 20
Form 3
0
0
No matching records found

Pulmatrix, Inc. (PULM) Snapshot price: $1.8

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Aug 28
Form 4
0
0
Apr 2
Form 4
0
0
Jan 9
Form 4
0
0
May 16
Form 4
0
0
Jun 5
Form 4
+50.30%
1.15M
3.44M
Apr 3
Form 4
0
0
Mar 20
Form 4
0
0
Feb 3
Form 4
0
0
Jun 24
Form 4/A
0
0
Jun 15
Form 4
2.29M
$6.88
2.29M
Jun 15 - Jun 16
Form 3
0
0
No matching records found